-transparent.png){kind=logo}
Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis. 1992
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
Department of Medicine, University of Western Ontario, London, Canada.
Two hundred and ninety-six patients were enrolled in a 6-month, open-label tolerability study of enteric-coated naproxen in patients with rheumatoid arthritis (n = 174) and osteoarthritis (n = 122). Thirty percent of the patients were greater than 65 years of age. Under standard clinical prescribing conditions, enteric-coated naproxen 500 mg twice daily and 375 mg twice daily demonstrated an acceptable tolerability profile that was not different from what one would expect with standard naproxen.
Related Publications
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
January 1992,
European journal of rheumatology and inflammation,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
January 1991,
Current medical research and opinion,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
April 1994,
The Journal of rheumatology,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
June 1990,
British journal of rheumatology,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
January 2000,
Clinical therapeutics,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
May 1981,
Rheumatology and rehabilitation,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
August 1985,
Bollettino chimico farmaceutico,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
January 1992,
European journal of rheumatology and inflammation,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
February 2004,
The Journal of rheumatology,
N Bellamy, and
A Beaulieu, and
C Bombardier, and
J Esdaile, and
S Huang, and
A V Jovaisas, and
V N Khanna, and
G Kraag, and
D M Mehta, and
H A Ménard
February 1988,
Seminars in arthritis and rheumatism,
